Skinvisible, Inc. (SKVI) Partnership with Quoin Focuses on Population’s Pain Needs

  • Non-binding proposed merger announced on November 27, 2017
  • Quoin merger expected to deliver non-opioid relief to post-surgical patients
  • Over-65 population with advanced pain needs expected to double within next 30 years
  • Skinvisible and Quoin proposed merger expected to deliver better results to patients

Health professionals are preparing for an expected doubling of the 65 years and older population within the next 30 years, creating medical need to address the pain that often becomes a prevalent companion to age. While modern pharmaceuticals have developed opioids and non-steroidal therapies for reducing chronic pain, the drugs are often accompanied by addiction and unwanted side effect concerns. However, Skinvisible, Inc.’s (OTCQB: SKVI) recently announced non-binding merger with Quoin Pharmaceuticals Limited is creating a partnership that may provide alternative solutions at a time when they are needed the most.

Quoin’s products include QRX001, which will provide 72 hours of effective non-opioid pain relief to post-surgical patients, and QRX002, which is an anticipated once-a-day solution for military PTSD patients at risk for suicidal tendencies. QRX001 will be formulated with an NMDA receptor antagonist that has undergone almost 30 pre-clinical trial studies in the United States. The studies have shown that…


More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

Leave a Reply